OTCPK:MDXG

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. More Details


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has MiMedx Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MDXG has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.8%

MDXG

-3.4%

US Biotechs

-2.4%

US Market


1 Year Return

29.0%

MDXG

35.9%

US Biotechs

18.2%

US Market

Return vs Industry: MDXG underperformed the US Biotechs industry which returned 39.3% over the past year.

Return vs Market: MDXG exceeded the US Market which returned 19.5% over the past year.


Shareholder returns

MDXGIndustryMarket
7 Day-2.8%-3.4%-2.4%
30 Day1.1%0.7%4.2%
90 Day20.4%-4.7%6.3%
1 Year29.0%29.0%38.3%35.9%20.9%18.2%
3 Year-42.0%-42.0%18.5%12.5%41.2%31.8%
5 Year-27.9%-27.9%17.2%8.9%84.8%63.9%

Price Volatility Vs. Market

How volatile is MiMedx Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MiMedx Group undervalued compared to its fair value and its price relative to the market?

30.59x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MDXG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MDXG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MDXG is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MDXG is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDXG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDXG is overvalued based on its PB Ratio (30.6x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is MiMedx Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

25.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MiMedx Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has MiMedx Group performed over the past 5 years?

-38.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MDXG is currently unprofitable.

Growing Profit Margin: MDXG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDXG is unprofitable, and losses have increased over the past 5 years at a rate of 38.2% per year.

Accelerating Growth: Unable to compare MDXG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDXG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: MDXG has a negative Return on Equity (-36.68%), as it is currently unprofitable.


Next Steps

Financial Health

How is MiMedx Group's financial position?


Financial Position Analysis

Short Term Liabilities: MDXG's short term assets ($107.6M) exceed its short term liabilities ($63.7M).

Long Term Liabilities: MDXG's short term assets ($107.6M) exceed its long term liabilities ($64.4M).


Debt to Equity History and Analysis

Debt Level: MDXG's debt to equity ratio (285.3%) is considered high.

Reducing Debt: MDXG had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: MDXG's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: MDXG is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is MiMedx Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDXG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDXG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDXG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDXG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Tim Wright (62 yo)

1.42yrs

Tenure

US$5,069,354

Compensation

Mr. Timothy R. Wright, also known as Tim, MBA, has been a Director of MiMedx Group, Inc. since June 17, 2019. He has been the Chief Executive Officer at MiMedx Group, Inc. since joined on May 13, 2019. Mr. ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD5.07M) is above average for companies of similar size in the US market ($USD2.82M).

Compensation vs Earnings: Insufficient data to compare Tim's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Wright
CEO & Director1.42yrsUS$5.07m0.63%
$ 4.5m
Peter Carlson
Chief Financial Officer0.58yrUS$1.93m0.079%
$ 553.5k
Scott Turner
Senior Vice President of Operations & Procurement3.5yrsUS$619.46k0.12%
$ 848.0k
William Phelan
Senior VP & Chief Accounting Officer0.42yrno datano data
Thomas Koob
Chief Scientific Officer14.75yrsUS$183.75kno data
Hilary Dixon
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Mark Graves
Senior VP & Chief Compliance Officer2.25yrsno data0.042%
$ 293.0k
William Hulse
General Counsel & Secretary0.83yrno datano data
David Mason
Chief Medical Officer1.83yrsno datano data
Stan Micek
Senior Vice President of Business Development & Portfolio Management0.58yrno datano data
Rohit Kashyap
Executive VP & Chief Commercial Officer0.17yrno data0.16%
$ 1.1m
Robert Stein
Executive Vice President of Research & Development0.17yrno data0.076%
$ 536.0k

0.8yrs

Average Tenure

56yo

Average Age

Experienced Management: MDXG's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Timothy Wright
CEO & Director1.42yrsUS$5.07m0.63%
$ 4.5m
James Bierman
Independent Director1.33yrsUS$243.04k0.060%
$ 421.6k
William Hawkins
Independent Preferred Director0.25yrno data0.024%
$ 171.8k
James Andrews
Member of Medical Advisory Boardno datano datano data
Charles Koob
Director12.58yrsUS$232.00k1.28%
$ 9.0m
Charles Evans
Independent Director8.08yrsUS$327.93k0.11%
$ 794.9k
K. Newton
Independent Director1.33yrsUS$240.91k0.060%
$ 421.6k
Thomas Zdeblick
Member of Medical Advisory Boardno datano datano data
Robert Guldberg
Member of Medical Advisory Boardno datano datano data
Glenn Gaston
Member of Medical Advisory Boardno datano datano data
Neil Yeston
Independent Director8.08yrsUS$282.13k0.12%
$ 827.6k
M. Behrens Wilsey
Independent Chairman of the Board1.33yrsUS$259.47kno data

1.3yrs

Average Tenure

67yo

Average Age

Experienced Board: MDXG's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MiMedx Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MiMedx Group, Inc.
  • Ticker: MDXG
  • Exchange: OTCPK
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$704.200m
  • Shares outstanding: 107.51m
  • Website: https://www.mimedx.com

Number of Employees


Location

  • MiMedx Group, Inc.
  • 1775 West Oak Commons Court, NE
  • Marietta
  • Georgia
  • 30062
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDXGOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 2008

Biography

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. I ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 01:07
End of Day Share Price2020/10/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.